Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) Gross margin
Bio-Techne Corp's gross margin over the twelve months to 30 June 2026 was 65.8%. Over the past ten years it has ranged from 64.8% (fiscal 2025) to 68.4% (fiscal 2022); the current reading is higher than 25% of that period. That is in line with the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2026 | 65.8% | 0.97 |
| FY2025 | 64.8% | (1.61) |
| FY2024 | 66.4% | (1.31) |
| FY2023 | 67.7% | (0.70) |
| FY2022 | 68.4% | 0.45 |
| FY2021 | 68.0% | 2.56 |
| FY2020 | 65.4% | (0.90) |
| FY2019 | 66.3% | (0.90) |
| FY2018 | 67.2% | 0.68 |
| FY2017 | 66.5% | (0.93) |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 65.8% | (1.06) |
| Mar 2026 | 66.9% | 2.23 |
| Dec 2025 | 64.7% | (1.00) |
| Sep 2025 | 65.7% | 2.93 |
| 42 more quarters | Free account |
Against its own ten years
Low 64.8%
High 68.4%
Ten-year median
66.9%
Current reading's percentile
25
Gross margin against peers
| Company | Gross margin |
|---|---|
| SMMT Summit Therapeutics PLC compare | 100.0% |
| CORT Corcept Therapeutics Incorporated compare | 98.3% |
| KRYS Krystal Biotech, Inc. compare | 94.6% |
| BBIO BridgeBio Pharma, Inc. compare | 94.4% |
| AXSM Axsome Therapeutics, Inc. compare | 93.2% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.5% |
| HALO Halozyme Therapeutics, Inc. compare | 82.4% |
| BMRN BioMarin Pharmaceutical Inc. compare | 76.1% |
| TECH Bio-Techne Corp | 65.8% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement